The Global Alliance for TB Drug Development (TB Alliance)

Tuberculosis (TB) is the leading infectious disease killer globally
Each year, 9 million people are infected with TB, of which 1.5 million people eventually die. Nearly all TB cases and deaths occur in the developing world and those afflicted everywhere are mostly the poorest and most vulnerable. Especially women and children are uniquely impacted by the disease as TB is the third most deadly killer of women of child-bearing age. Each year, one million children get sick with TB and approximately 10 million children are orphaned by the disease. TB is also the leading cause of death among people living with HIV; one in four deaths of people with HIV is due to TB. Despite the massive threat of TB, treatment is wholly inadequate. The length and complexity of treatment has resulted in widespread drug-resistant TB. Treating drug-resistant TB is ineffective, toxic, and prohibitively expensive.

TB Alliance aims to develop an affordable “universal” treatment regimen for TB
TB Alliance’s mission is to dramatically impact the tuberculosis pandemic by developing new, faster-acting and affordable TB treatments that are available to those who need them. The ultimate vision of the organization is to develop an ultra-short “universal” treatment that can cure all forms of TB. During the period 2016-2020, TB Alliance plans to make considerable progress toward this vision by introducing new combination treatments (also called “regimens”) that would shorten and improve treatment for drug-sensitive and some forms of drug-resistant TB as well as advance at least three new drugs into human studies.

Today, treatment for drug-sensitive TB takes a minimum of six months with four drugs and treatment for drug-resistant TB can take two years, or even longer, with the potential for a dozen or more pills and injections. In the period 2016-2020, among other programs, TB Alliance plans to create a shorter and better regimen by introducing a new four-month regimen for drug-sensitive TB and a new six-month regimen for many people with multi drug-resistant (MDR-TB). This will be the first significant improvement to the standard of care in drug-sensitive TB in more than 40 years and the first treatment shortening and simplification for MDR-TB treatment ever. At the same time, TB Alliance is optimistic that a novel approach initiated in 2015 to test the first new treatment for extensively drug-resistant (XDR-TB) – where today, few patients survive – will be successful and at a minimum lead to a new six to nine month all-oral drug regimen for people with no other options. Product Development Partnerships (PDP) amplify impact TB Alliance brings together drug trial sponsors to develop the best TB drug regimens, regardless of which drug happens to belong to which sponsor. This collaboration forges partnerships among pharmaceutical companies and other drug developers, regulatory agencies, and non-profits to support advances in regulatory science, the development of infrastructure, and other progress needed to facilitate the development and availability of new TB treatments.
This approach shortens the time it takes to introduce impactful TB drug regimens by decades and significantly reduces costs. Such a consortium would not have been possible without a PDP such as TB Alliance.

TB Alliance catalyzed the TB drug development field by drawing in industry, non-profit partners, and communities affected by TB as well as marshalling resources to develop and advance new TB treatment regimens. Cost-sharing approaches are also piloted in South Africa, China, and Brazil, accelerating development in these high-burden countries as well as adding funding, expertise, and infrastructure. TB Alliance’s strategy for manufacturing partnerships is important to create sustainability and to engage the private sector in a key and expensive part of the product development cycle. Earlier funding by the Netherlands Ministry of Foreign Affairs (MoFA)

TB Alliance is now poised to advance promising drug combinations into the last stages of testing before they can be made globally available. This is only possible because of previous support from the Netherlands Ministry of Foreign Affairs, which helped ensure that novel drugs from new drug classes are now available. MoFA’s previous investment has also laid the groundwork to allow TB Alliance to bring one or more new drug candidates into preclinical development per year. This ensures a more promising pipeline for the future of TB treatment.

| Total budget lead applicant (5 years) | € 162,992,718 |
| Contribution by the Netherlands Ministry of Foreign Affairs | € 15,300,000 |

Contact details TB Alliance
TB Alliance, Senior Vice President for External Affairs
40 Wall Street, 24th floor, New York, NY 10005
T +1 212 227 7540
Willo.Brock@tballiance.org

Contact RVO.nl
T +31 088 042 42 42
pdp@rvo.nl
www.rvo.nl/pdp

About RVO.nl
Your ambitions include doing business in emerging markets and developing countries. You want to contribute towards a healthy local business and the sustainable economic development of a country. Sometimes you encounter obstacles in relation to financing, a lack of knowledge about market opportunities, or the absence of a business network. You also have to deal with Corporate Social Responsibility and other laws and regulations. For all these questions relating to international enterprise, contact the Netherlands Enterprise Agency. We are your partner in the area of Sustainable, Agricultural, Innovative and International enterprise. For more information, visit www.rvo.nl.

This is a publication of:
Netherlands Enterprise Agency
Prinses Beatrixlaan 2 | 2595 AL The Hague
P.O. Box 10366 | 2501 HJ The Hague
T +31 (0) 88 042 42 42
F +31 (0) 88 602 90 24
www.rvo.nl/pdp
E pdp@rvo.nl

This publication has been commissioned by the Ministry of Foreign Affairs.
© Netherlands Enterprise Agency | February 2016